[HTML][HTML] Lemzoparlimab, a differentiated anti-cd47 antibody in combination with rituximab in relapsed and refractory non-Hodgkin's lymphoma: initial clinical results
A Mehta, W Harb, C Xu, Y Meng, L Lee, V Yuan… - Blood, 2021 - Elsevier
Introduction Lemzoparlimab (also known as TJ011133 or TJC4) is a differentiated CD47
IgG4 antibody targeting a distinct CD47 epitope to enable a unique red blood cell sparing …
IgG4 antibody targeting a distinct CD47 epitope to enable a unique red blood cell sparing …
385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results
J Berlin, W Harb, A Adjei, Y Xing, P Swiecicki… - 2020 - jitc.bmj.com
Background CD47 blockade using SIRPα-Fc or anti-CD47 antibodies results in inhibition of
the 'do not eat'signal and activation of phagocytosis and has emerged as a promising cancer …
the 'do not eat'signal and activation of phagocytosis and has emerged as a promising cancer …
607 TJ210 (MOR210), a differentiated anti-C5aR antibody for anti-cancer therapy
J Meng, Z Wang, W Cao, C Chen, JH Shen… - 2020 - jitc.bmj.com
Background Extensive investigations into the tumor microenvironment (TME) have
uncovered molecular mechanisms linking aberrant complement activation and cancer …
uncovered molecular mechanisms linking aberrant complement activation and cancer …
[CITATION][C] The Efficacy and Safety of Once-Weekly Dosing of Polyethylene Glycol Loxenatide (PEX168) as an Add-on Therapy to Metformin in Chinese Patients with …
XP Chen, WY Yang, XF Lv, GY Yang… - …, 2014 - AMER DIABETES ASSOC 1701 N …